Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group AG    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/18/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
582.8(c) 580(c) 593.4(c) 595.2(c) 599.2(c) Last
192 337 310 190 246 838 165 053 192 630 Volume
-0.78% -0.48% +2.31% +0.30% +0.67% Change
More quotes
Financials
Sales 2020 6 161 M 6 952 M 6 952 M
Net income 2020 844 M 953 M 953 M
Net Debt 2020 2 915 M 3 289 M 3 289 M
P/E ratio 2020 51,8x
Yield 2020 0,49%
Sales 2021 6 546 M 7 387 M 7 387 M
Net income 2021 969 M 1 093 M 1 093 M
Net Debt 2021 2 448 M 2 762 M 2 762 M
P/E ratio 2021 45,0x
Yield 2021 0,53%
Capitalization 44 514 M 50 271 M 50 229 M
EV / Sales 2020 7,70x
EV / Sales 2021 7,17x
Nbr of Employees 15 913
Free-Float 99,6%
More Financials
Company
Lonza Group is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals and nutritional ingredients (70.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, nutritional ingredients, etc. In addition, the group offers dosage solutions for... 
More about the company
Notations Surperformance© of Lonza Group AG
Trading Rating : Investor Rating :
More Ratings
All news about LONZA GROUP AG
01/20LONZA : NextPharma Set to Acquire Two Lonza Sites Specialized in Lipid Oral Dosa..
AQ
01/19LONZA : Aruvant chooses Lonza to Manufacture ARU-1801 a Potentially curative Tre..
AQ
01/19LONZA : Signs Agreement to Sell Two Sites to NextPharma
DJ
01/19LONZA : to Divest Two Lipid Oral Dosage Producing Sites in France, UK, to NextPh..
MT
01/18LONZA : to Manufacture Sickle Cell Disease Therapy for Aruvant Sciences
MT
01/18LONZA : Aruvant chooses Lonza to Manufacture ARU-1801, a Potentially curative Tr..
PU
01/17LONZA : Partner Moderna to Deliver 7.5 Million COVID-19 Shots to Switzerland By ..
MT
01/15GLOBAL MARKETS LIVE: Citigroup, Wells Fargo, SAP…
01/15LONZA : Invitation to Lonza's Full-Year Results 2020 Conference Call and Webcast
PU
01/14Lonza Group Awaits Swiss Regulator Licensing For Moderna Vaccine Ingredients
MT
01/13Swissmedic Green-lights COVID-19 Vaccine Developed By Lonza Partner Moderna
MT
01/12LONZA : Joins Capricor Therapeutics to Develop Treatment for Muscular Dystrophy,..
MT
01/12Swissmedic OKs COVID-19 Vaccine By Lonza Partner Moderna
MT
01/12CAPRICOR THERAPEUTICS : Partners With Lonza to Develop Lead Cell Therapy Product..
MT
01/11LONZA : Kicks Off Manufacturing of Ingredients for Moderna's COVID-19 Shot
MT
More news
News in other languages on LONZA GROUP AG
01/22LONZA GROUP AG : Veröffentlichung des Jahresergebnisses
01/22LONZA GROUP AG : publication des résultats annuels
01/19Lonza boudé, dans la foulée de désinvestissements
01/19Wall Street revient dans la danse avec une pointe d'optimisme
01/19EN DIRECT DES MARCHES : Danone, Engie, Veolia / Suez, ADP, Alstom, ThyssenKrupp,..
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Stock Trading Strategies
LONZA GROUP AG - 2020
The stock is approaching a major resistance level
BUY
More Stock Trading Analysis
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | LONN | CH0013841017 | MarketScreener
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 610,79 CHF
Last Close Price 599,20 CHF
Spread / Highest target 29,1%
Spread / Average Target 1,93%
Spread / Lowest Target -31,6%
EPS Revisions
Managers and Directors
NameTitle
Pierre-Alain Ruffieux Chief Executive Officer
Albert M. Baehny Chairman
Rodolfo Savitzky Chief Financial Officer
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG5.34%50 271
MODERNA, INC.25.41%51 846
CELLTRION, INC.-13.65%38 245
IQVIA HOLDINGS INC.3.58%35 582
SEAGEN INC.4.35%33 059
HANGZHOU TIGERMED CONSULTING CO.,LTD13.79%24 266